Stock Analiz

UroGen Pharma Ltd. (URGN) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

UroGen Pharma’s revenue went from $18M in fiscal 2016 to $110M in fiscal 2025, growth of about 22.6% a year.

Net income in fiscal 2025 was -$153M, a net margin of -139.8%; the best year in this period was 2016 with -$2M.

Over the twelve months to September 30, 2026, revenue was $250M and net income -$66M.

Free cash flow was -$163M in fiscal 2025 and positive in 1 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $18M162017: $8M172018: $1M182019: $18000192020: $12M202021: $48M212022: $64M222023: $83M232024: $90M242025: $110M25$110M
Net income
2016: -$2M162017: -$20M172018: -$76M182019: -$105M192020: -$128M202021: -$111M212022: -$110M222023: -$102M232024: -$127M242025: -$153M25-$153M
Free cash flow
2016: $3M162017: -$10M172018: -$38M182019: -$71M192020: -$107M202021: -$86M212022: -$88M222023: -$77M232024: -$97M242025: -$163M25-$163M
EPS (diluted)
2016: $-0.04162017: $-0.41172018: $-1.54182019: $-2.14192020: $-2.62202021: $-2.26212022: $-2.24222023: $-2.08232024: $-2.59242025: $-3.1325$-3.13

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$250M$110M$90M$83M$64M$48M$12M$18000$1M$8M$18M
Gross profit$229M$97M$82M$73M$57M$43M$11M$18000-$675000$8M$18M
Operating income-$31M-$125M-$97M-$66M-$79M-$92M-$127M-$109M-$77M-$20M$798000
Net income-$66M-$153M-$127M-$102M-$110M-$111M-$128M-$105M-$76M-$20M-$2M
EPS (diluted)$-1.31$-3.13$-2.59$-2.08$-2.24$-2.26$-2.62$-2.14$-1.54$-0.41$-0.04
R&D$73M$67M$57M$46M$53M$48M$47M$49M$37M$19M—
Revenue growth—+21.4%+9.3%+28.5%+34.0%+307.2%+65450.0%−98.4%−86.2%−53.5%—

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$132M-$162M-$97M-$76M-$88M-$85M-$106M-$71M-$37M-$10M$4M
Capital spending-$203000-$289000-$295000-$194000-$254000-$752000-$1M-$325000-$560000-$271000-$695000
Free cash flow-$132M-$163M-$97M-$77M-$88M-$86M-$107M-$71M-$38M-$10M$3M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$19M$12M$13M$9M$11M$23M$28M$30M$31M$6M$2M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$160M$283M$151M$100M$89M$102M$147M$101M$73M$21M
Debt—$128M$123M$100M$100M$1M$3M$4M$3M——
Equity—-$105M-$9M-$65M-$89M$8M$96M$180M$90M$69M$16M
Total assets—$200M$286M$178M$136M$120M$122M$202M$104M$76M$23M
Shares (diluted)50M49M49M49M49M49M49M49M49M49M49M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin91.4%88.7%90.2%88.7%88.1%89.3%91.5%100.0%-59.8%92.7%99.8%
Operating margin-12.4%-113.7%-107.1%-79.2%-122.8%-192.1%-1074.2%-608200.0%-6842.2%-244.6%4.5%
Net margin-26.3%-139.8%-140.3%-123.6%-170.6%-230.7%-1088.9%-584100.0%-6707.2%-245.2%-11.1%
FCF margin-52.8%-148.2%-107.4%-92.6%-136.5%-178.3%-907.7%-396300.0%-3359.4%-120.6%19.9%
ROIC—-435.4%-67.2%-147.9%-583.4%-736.5%-101.1%-46.9%-65.2%-23.0%3.9%
ROE—145.5%1441.3%156.8%122.8%-1317.2%-133.3%-58.3%-84.0%-29.2%-11.9%

Frequently asked questions

What is UroGen Pharma’s annual revenue?

$110M in fiscal 2025 and $250M over the twelve months to September 30, 2026.

How much profit does UroGen Pharma make?

Net income was -$153M in fiscal 2025 (net margin -139.8%).

Is UroGen Pharma’s revenue growing?

Yes: revenue rose 21.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.